Cytokinetics, Inc. (CYTK)

[Solantey]

I'm expecting upgrades from major brokerages soon. Accumulation of cheap shares continue. Expecting coverage initiation soon with "BUY" ratings and price targets in the $10-$12 range.

Individuals that sold on April 25 can rebuy on Tuesday and under the "wash rule" be able to utilize any losses incurred.

$CYTK is substantially undervalued based on a reasonable assessment of the company's tremendous potential with two partnerships in place and over $1B in milestone payments + royalties expected over the next two years. The company has over $100M in cash on hand and more milestone payments expected.

There is a strong possibility that Cytokinetics will partner with Amgen to move BENEFIT-ALS into phase 3 trials. I think there is also a strong possibility that Amgen will make a buyout offer for Cytokinetics within the next twelve months.

Current fair value is a minimum of $9.00.

All IMHO.